Revance and Teoxane's HA filler clears for infraorbital hollowing, expanding the under-eye injectables category.
The FDA has approved RHA Redensity Eye for correction of infraorbital hollowing, marking the first HA filler cleared specifically for the under-eye compartment. The approval follows Revance and Teoxane's submission and represents a distinct clinical indication from existing volumizers.
RHA Redensity Eye is formulated with resilient hyaluronic acid technology designed to maintain projection and movement in the delicate periorbital zone. The under-eye hollows segment has grown as a discrete treatment category—distinct from tear trough filler and broader midface volume restoration—driven by patient demand for subtle, non-surgical correction of age-related volume loss.
First HA filler cleared specifically for infraorbital hollowing.
For practice owners, this approval opens a dedicated SKU conversation with patients seeking targeted under-eye correction and may shift economics on per-syringe allocation if adoption tracks the broader RHA franchise momentum.
Source: original report ↗
Free alerts
Free: recall & rule-change alerts for your practice.
Get the recalls and state-law changes that hit your treatment room, in your inbox — free. Unsubscribe in one click.
Free · weekly · unsubscribe anytime. Privacy.
Stay three moves ahead of every practice in your market.
Knowing it happened is table stakes. Inside MedSpa Pro hands you the play — what each move means for your margins, your license, and your patients, and exactly what to do about it — in a two-minute brief, twice a week. The owners who read it never get blindsided.
Get the edge · $20/mo
Join the owners who run ahead of the industry. Cancel anytime, one click.
